GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncologix Tech OCLG · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

+9900.00%

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2017

Revenue

$2.9m

FY2014FY2017

Net income

−$2.4m

FY2014FY2017

Free cash flow

−$25,117

FY2014FY2017

Shareholders' equity

−$6.0m

FY2014FY2017

Income statement

Fiscal years

FY2017FY2016FY2015FY2014
Revenue$2.9m$4.0m$4.9m$3.7m
Research and development———$30,000
Operating income−$865,000−$512,000−$509,000−$572,000
Net income−$2.4m−$1.8m−$2.6m−$1.3m
Diluted earnings per share-0.00-0.00-0.00-0.01

Balance sheet

At each fiscal year end

FY2017FY2016FY2015FY2014
Total assets$1.5m$2.2m$3.1m$2.1m
Cash and short-term investments$30,834$60,189$24,993$17,504
Total liabilities$7.5m$5.8m$5.0m$2.8m
Debt$5.2m$4.4m$3.4m$1.9m
Shareholders' equity−$6.0m−$3.6m−$1.8m−$664,718
Shares outstanding773m737m669m133m

Cash flow

Fiscal years

FY2017FY2016FY2015FY2014
Cash from operations−$24,204$344,918−$356,544−$629,942
Capital spending−$913−$913−$3,264−$878
Free cash flow−$25,117$344,005−$359,808−$630,820

Latest quarters

By quarter end

Nov 2022Nov 2017Aug 2017May 2017Feb 2017Nov 2016Aug 2016May 2016
Revenue—$618,529$702,145$842,637$568,554$736,623$897,141$813,186
Operating income−$18,770−$58,531−$361,000$49,107−$394,000−$159,000−$357,000−$95,089
Net income−$18,774−$231,000−$1.3m−$190,000−$593,000−$292,000−$1.1m−$264,000
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets$4,850$1.5m$1.5m$1.8m$1.8m——$3.1m
Cash and short-term investments$4,850——————$86,315
Debt—$5.1m$5.2m$4.2m$4.1m——$4.0m
Shareholders' equity−$18,774−$6.2m−$6.0m−$4.7m−$4.5m——−$2.6m

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%103%211%-57%4355%5233%25500%1092167%800%10353%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-to-1 reverse split · 19 May 2011

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.